主要文件

查看所有文档

P2116

吡非尼酮

Name: 吡非尼酮
Brand: SIGMA

≥97% (HPLC), powder, antifibrotic agent

别名:

5-甲基-1-苯基-2-(1H)-吡啶酮

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₂H₁₁NO

化学文摘社编号:

53179-13-8

分子量:

185.22

UNSPSC Code:

12352200

PubChem Substance ID:

24278625

NACRES:

NA.77

MDL number:

MFCD00866047

Assay:

≥97% (HPLC)

Form:

powder

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

吡非尼酮, ≥97% (HPLC)

Quality Level

100

assay

≥97% (HPLC)

form

powder

solubility

H₂O: >10 mg/mL at 60 °C (warming for 30 minutes), DMSO: >20 mg/mL

originator

Shionogi

SMILES string

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3

InChI key

ISWRGOKTTBVCFA-UHFFFAOYSA-N

说明

General description

吡非尼酮（5-甲基-1-苯基-2-[1H]-吡啶酮）是合成的吡啶衍生物。

Application

吡非尼酮用于：

作为兔的术后滴眼剂，分析其抗纤维化作用，改进青光眼滤过手术
作为抗瘢痕形成剂，检查其是否影响兔植入青光眼引流装置（GDD）后的异物反应
在人眼眶成纤维细胞（hOF）原代培养物中测试其抗纤维化潜力
作为肿瘤坏死因子（TNFα）抑制剂，研究其在缺氧中的作用

Biochem/physiol Actions

吡非尼酮用于治疗特发性肺纤维化（IPF）。有助于减少肺功能下降引起的衰弱，延长无进展生存期。吡非尼酮可抑制人Tenon′s 囊成纤维细胞胶原蛋白的增殖和收缩。

吡非尼酮可抑制胶原生成和成纤维细胞增殖。在多种肺纤维化动物模型和临床试验中显示出抗纤维化和抗炎属性。

抑制胶原生成和成纤维细胞增殖。

Features and Benefits

该化合物由 Shionogi 开发。如需浏览其他制药公司开发的化合物和批准的药物/候选药物列表，请点击此处。

Still not finding the right product?

Explore all of our products under 吡非尼酮

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Arata Azuma

Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)

Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the

CX3CL1 (fractalkine) and TNF alpha production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling

Szukiewicz D, et al.

Inflammation Research, 63(3), 179-189 (2014)

Current and novel drug therapies for idiopathic pulmonary fibrosis.

Huzaifa I Adamali et al.

Drug design, development and therapy, 6, 261-272 (2012-10-12)

Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the

查看所有相关文献

全球贸易项目编号

货号	GTIN
P2116-10MG	04061834362500
P2116-50MG	04061834362517